Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
17 pending office actions • 10 art units • 16 examiners • 0 of 17 (0%) have an AI response strategy ready • 18 patents granted in the last 365 days
LTS Lohmann Therapie-Systeme AG has 15 pending office actions in Biotechnology & Pharmaceuticals. The portfolio involves 15 examiners across 9 art units. Each pending action has a distinct examiner, while some art units contain more than one matter, providing a basis for technical grouping despite the examiner-level dispersion.
MACFARLANE, EVAN H is the busiest examiner, with 1 pending matter. No examiner has a larger assignment, so the workload is spread evenly across the recorded examiner relationships. Counsel should use art-unit groupings for shared technical review while maintaining separate response plans for each examiner.
This structure places a premium on centralized docket control and consistent claim terminology. It also limits the value of relying on one examiner-specific prosecution history, because every matter has a distinct examiner assignment.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 7 (41%) |
| Double-patenting + other | 1 (6%) |
| Multi-statute (no §101) | 9 (53%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KETCHAM, KAREN A | 2 | 19.6% | +37.2% |
| MACFARLANE, EVAN H | 1 | 50.7% | +42.3% |
| SHOMER, ISAAC | 1 | 63.1% | +30.5% |
| ALLEY, GENEVIEVE S | 1 | 60.5% | +48.3% |
| ABU-DAYEH, TAGWA MOHAMMAD | 1 | — | — |
| HARM, NICKOLAS R | 1 | 79.5% | +5.8% |
| BAZARGANI, ARYA AHMADI | 1 | 62.5% | +31.3% |
| SANDERS, JAMES M | 1 | 55.0% | +27.1% |
| NGUYEN, LAM S | 1 | 78.9% | +0.3% |
| GREENE, IVAN A | 1 | 18.8% | +6.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17421265 | ORAL THIN FILM | KIM, DANIELLE A | 37d overdue |
| 16625401 | SELF-REMINDING PATCH | YU, HONG | 30d overdue |
| 17278844 | TRANSDERMAL THERAPEUTICS SYSTEM WITH BARRIER LAYER | KETCHAM, KAREN A | 8d |
| 17423653 | Support for Microneedle Array | DOUBRAVA, JOHN A | 21d |
| 18947030 | Device and Method for Removing a Section from a Web and System for Processing a Web | MACFARLANE, EVAN H | — |
| 18692408 | RAPIDLY DISINTEGRATING ORAL THIN-FILMS/FOAMS HAVING A HIGH ACTIVE-INGREDIENT CONTENT BASED ON A MIXTURE OF POLYVINYL ALCOHOLS HAVING VARIOUS MOLECULAR WEIGHTS | ALLEY, GENEVIEVE S | — |
| 18683548 | Microneedle Device and Method for Detecting At Least One Force Acting on a Microneedle Array | ABU-DAYEH, TAGWA MOHAMMAD | — |
| 18283560 | Method and Device for Manufacturing an Adherent Film Composite | HARM, NICKOLAS R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17278844 | TRANSDERMAL THERAPEUTICS SYSTEM WITH BARRIER LAYER | KETCHAM, KAREN A | 8d |
| 18947030 | Device and Method for Removing a Section from a Web and System for Processing a Web | MACFARLANE, EVAN H | — |
| 18699714 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF TIZANIDINE | SHOMER, ISAAC | — |
| 18692408 | RAPIDLY DISINTEGRATING ORAL THIN-FILMS/FOAMS HAVING A HIGH ACTIVE-INGREDIENT CONTENT BASED ON A MIXTURE OF POLYVINYL ALCOHOLS HAVING VARIOUS MOLECULAR WEIGHTS | ALLEY, GENEVIEVE S | — |
| 18548690 | ORAL THIN FILM | BAZARGANI, ARYA AHMADI | — |
| 18275694 | Method for Manufacturing a Mold Element for the Production of Micro-arrays and a Mold Element | SANDERS, JAMES M | — |
| 17298551 | TRANSDERMAL THERAPEUTIC SYSTEM WITH DIFFUSION BARRIER | KETCHAM, KAREN A | — |
| Art Unit | Apps |
|---|---|
| 3783 | 4 |
| 1614 | 3 |
| 1613 | 2 |
| 1619 | 2 |
| 3724 | 1 |
| 1612 | 1 |
| 1617 | 1 |
| 1745 | 1 |
| 1743 | 1 |
| 2853 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18947030 | Device and Method for Removing a Section from a Web and System for Processing a Web | MACFARLANE, EVAN H | 3724 | §102§103§112 | Final Rejection | — | Pending | Nov 14, 2024 |
| 18699714 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF TIZANIDINE | SHOMER, ISAAC | 1612 | §103 | Final Rejection | — | Pending | Apr 09, 2024 |
| 18692408 | RAPIDLY DISINTEGRATING ORAL THIN-FILMS/FOAMS HAVING A HIGH ACTIVE-INGREDIENT CONTENT BASED ON A MIXTURE OF POLYVINYL ALCOHOLS HAVING VARIOUS MOLECULAR WEIGHTS | ALLEY, GENEVIEVE S | 1617 | §103§112 | Final Rejection | — | Pending | Mar 15, 2024 |
| 18683548 | Microneedle Device and Method for Detecting At Least One Force Acting on a Microneedle Array | ABU-DAYEH, TAGWA MOHAMMAD | 3783 | §103§112 | Final Rejection | — | Pending | Feb 14, 2024 |
| 18283560 | Method and Device for Manufacturing an Adherent Film Composite | HARM, NICKOLAS R | 1745 | §103§112 | Final Rejection | — | Pending | Sep 22, 2023 |
| 18548690 | ORAL THIN FILM | BAZARGANI, ARYA AHMADI | 1613 | §103DP | Final Rejection | — | Pending | Sep 01, 2023 |
| 18275694 | Method for Manufacturing a Mold Element for the Production of Micro-arrays and a Mold Element | SANDERS, JAMES M | 1743 | §103 | Non-Final OA | — | Pending | Aug 03, 2023 |
| 18272678 | Test Equipment for Microneedle Systems, and a Test System and a Method for Testing a Microneedle Application | NGUYEN, LAM S | 2853 | §103 | Final Rejection | — | Pending | Jul 17, 2023 |
| 18210144 | MICRONEEDLE SYSTEM FOR THE DELIVERY OF INTERFERON | GREENE, IVAN A | 1619 | §102§103§112Other | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18266740 | Active Ingredient Delivery System | MARRISON, SAMUEL JOSEPH | 3783 | §103 | Non-Final OA | — | Pending | Jun 12, 2023 |
| 18038829 | Sensor Device, Use of a Sensor Device, and Method for Detecting the Properties of a Skin Area | PRETLOW, DEMETRIUS R | 3783 | §102§103 | Non-Final OA | — | Pending | May 25, 2023 |
| 17786235 | TRANSMUCOSAL THERAPEUTIC SYSTEM CONTAINING AGOMELATINE | KASSA, TIGABU | 1619 | §103 | Final Rejection | — | Pending | Jan 31, 2023 |
| 17423653 | Support for Microneedle Array | DOUBRAVA, JOHN A | 3783 | §103§112 | Final Rejection | 21d | Pending | Jul 16, 2021 |
| 17421265 | ORAL THIN FILM | KIM, DANIELLE A | 1613 | §103§112 | Final Rejection | 37d overdue | Pending | Jul 07, 2021 |
| 17298551 | TRANSDERMAL THERAPEUTIC SYSTEM WITH DIFFUSION BARRIER | KETCHAM, KAREN A | 1614 | §103 | Final Rejection | — | Pending | May 29, 2021 |
| 17278844 | TRANSDERMAL THERAPEUTICS SYSTEM WITH BARRIER LAYER | KETCHAM, KAREN A | 1614 | §103 | Final Rejection | 8d | Pending | Mar 23, 2021 |
| 16625401 | SELF-REMINDING PATCH | YU, HONG | 1614 | §103§112 | Non-Final OA | 30d overdue | Pending | Dec 20, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLTS Lohmann Therapie-Systeme AG has 17 pending office actions as of October 2026, spread across 10 art units and 16 examiners.
Karen A Ketcham has the most, with 2 of LTS Lohmann Therapie-Systeme AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
